ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH EVAN YU
Management of mCRPC using Sipuleucel-T

VIEW ALL mCRPC VIDEOS

ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH JACOB BERCHUCK & MARY-ELLEN TAPLIN
Genetic Risk in Prostate Cancer

VIEW ALL PROSTATE CANCER VIDEOS

ASCO 2019 ANNUAL MEETING

ASCO 2019 ANNUAL MEETING

INTERVIEW WITH KARIM FIZAZI
ARAMIS Trial in Prostate Cancer: Impact of Darolutamide on Pain and Quality of Life

VIEW ALL nmCRPC VIDEOS

EAU 2019 ANNUAL MEETING

EAU 2019 ANNUAL MEETING

INTERVIEW WITH THOMAS POWLES
Immunotherapy in the Peri-Operative Setting for Bladder Cancer

VIEW ALL BLADDER CANCER VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Featured Videos

GU Cancers Symposium 2014 - Dissecting the biology of the androgen receptor pathway - Session Highlights

SAN FRANCISCO, CA USA (UroToday.com) - Dr. Peter Nelson opened the 2014 GU Cancers Symposium meeting by highlighting some new findings regarding the role of androgen receptor (AR) in prostate cancer.

He reviewed some recent findings showing that androgen-AR interactions mediate genotoxic stress, in addition to more canonical AR-mediated transcriptional programs.

gucancerssympalt thumbTwo studies published in the last 5 years have shown that androgen-AR interactions actually induce intranuclear proximity of genomic loci which facilitates creation of recurrent genetic rearrangements that are seen clinically -- such as those involving the TMPRSS2-ERG translocations. Not only do androgen-AR interactions juxtapose these genomic loci, but they also recruit enzymes which mediate double-strand DNA breaks (DSBs) and error-prone DNA repair. This process results in TMPRSS2 translocations.

Dr. Nelson also nicely laid the framework for other speakers by reviewing androgen and AR dependence in the natural history of prostate cancer. He pointed out that there are 4 states which define the AR program: endocrine androgen activation of AR, intracrine androgen activation of AR, ligand-dependent but still AR-dependent, and finally AR-indepenent. The highlight of the talk was his outline of reasons for the prostate cancer community to be both optimistic and pessimistic about curing prostate cancer using AR-based therapies.

Highlights of a presentation by Peter Nelson, MD at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

Fred Hutchinson Cancer Research Center, Seattle, WA USA 

Written by Phillip Abbosh, MD, PhD, medical writer for UroToday.com


View Full 2014 GU Cancers Symposium Coverage

 

 

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 4 Issue 1

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe